



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/155,590
Filing Date	30 September 1998
First Named Inventor	Jeffrey Schlom
Group Art Unit	1642
Examiner Name	Karen A. Canella
Attorney Docket Number	38163-0061

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A	SAMIR N. KHLEIF et al., "A Phase I Vaccine Trial With Peptides Reflecting <i>ras</i> Oncogene Mutations of Solid Tumors", <i>Journal of Immunotherapy</i> 22(2):155-165, 1999 Lippincott Williams & Wilkins, Inc., Philadelphia, PA.	
	B	SCOTT I. ABRAMS et al., "Generation of Stable CD4 and CD8 T Cell Lines from Patients Immunized with <i>ras</i> Oncogene-Derived Peptides Reflecting Codon 12 Mutations", <i>Cellular Immunology</i> 182:137-151, 1997 Academic Press, USA.	
	C	KWONG Y. TSANG et al., "Induction of Human Cytotoxic T Cell Lines Directed Against Point-Mutated p21 Ras-Derived Synthetic Peptides", <i>Vaccine Research</i> 3(4):183-193, 1994 Mary Ann Liebert, Inc., USA.	
	D	KATE J. GREEN et al., "Potent T cell response to a class I-binding 13-mer viral epitope and the and the influence of HLA micropolymorphism in controlling epitope length", <i>European Journal of Immunology</i> 34:2510-2518, 2004 Wiley-VCH Verlag GmbH & Co., KGaA, Weinheim, GERMANY.	
	E	SCOTT I. ABRAMS et al., Chapter 16 " <i>ras</i> Oncogene Products as Tumor-Specific Antigens for Activation of T-Lymphocyte-Mediated Immunity", <i>Gene Therapy of Cancer</i> , pp. 251-269, 1999 Academic Press, USA.	

Examiner
Signature

/Karen A. Canella/

Date
Considered

7/15/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

All references considered except where lined through. /KAC

/Karen A. Canella/ 7/15/2009/